

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Proposed Information Collection Activity; Comment Request**

**Proposed Projects**

*Title:* Interstate Administrative Subpoena and Notice of Interstate Lien.  
*OMB No.:* 0970–0152.

*Description:* Section 452(a)(11) of the Social Security Act requires the Secretary of the Department of Health and Human Services to promulgate a form for administrative subpoenas and imposition of liens used by State child support enforcement (title IV–D) agencies. The Interstate Administrative Subpoena is used to collect information for the establishment, modification and enforcement of child support orders in interstate cases. Section 454(9)(E) of the Social Security Act requires each State to cooperate with any other State in

using the federal form for issuance of administrative subpoenas and imposition of liens in interstate child support cases. Tribal IV–D agencies are not required to use this form but may choose to do so. OMB approval of these forms are expiring in December, 2016 and the Administration for Children and Families is requesting an extension of this form.

*Respondents:* State, local or Tribal agencies administering a child support enforcement program under title IV–D of the Social Security Act.

**ANNUAL BURDEN ESTIMATES**

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Administrative Subpoena .....	31,344	1	0.50	15,672
Notice of Lien .....	1,916,891	1	0.25	479,223

*Estimated Total Annual Burden Hours:* 494,895.

In compliance with the requirements of section 506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 330 C Street SW., Washington DC 20201. Attn: ACF Reports Clearance Officer. Email address: [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov). All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

**Robert Sargis,**  
*Reports Clearance Officer.*

[FR Doc. 2016–11633 Filed 5–17–16; 8:45 am]

**BILLING CODE 4184–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Office of the Assistant Secretary; Statement of Delegation of Authority**

Notice is hereby given that on January 27, 2016, the Assistant Secretary for Children and Families re-delegated certain responsibilities under the Trafficking Victims Protection Act of 2000 (TVPA), as amended, to the Director of the Office on Trafficking in Persons (OTIP), an office within the Immediate Office of the Assistant Secretary. In addition, the Assistant Secretary delegated to OTIP other authorities under sections 107(b) and 107(f) of the TVPA. By virtue of these re-delegations, certain previously delegated authorities to the Office of Refugee Resettlement (ORR) were rescinded.

By virtue of the authority vested in the Assistant Secretary by the Secretary of Health and Human Services on April 30, 2004, I rescinded the following delegation to the Director of ORR made on January 11, 2008 (73 FR 5198) and re-delegated the responsibilities to the Director of OTIP, with the authority to re-delegate:

Authority to conduct public awareness and information activities under section 106(b) of the TVPA (22 U.S.C. 7104(b)).

By virtue of the authority vested in the Assistant Secretary by the Secretary of Health and Human Services on March 28, 2001 (66 FR 18642), I rescinded the following delegation to the Director of ORR made on April 10, 2001 (66 FR

19960–61) and re-delegated the responsibilities to the Director of OTIP, with authority to re-delegate:

Authority to conduct certification activities under section 107(b)(1) of the TVPA, (22 U.S.C. 7105(b)(1)). In exercising this authority, personnel in OTIP will consult with the Secretary of Homeland Security.

By virtue of the authority vested in the Assistant Secretary by the Secretary of Health and Human Services on March 23, 2009 (74 FR 14564), I rescinded the following delegations to the Director of ORR made on April 10, 2009 (74 FR 19233) and re-delegated the responsibilities to the Director of OTIP, with authority to re-delegate:

Authority under section 107(b)(1) of the TVPA (22 U.S.C. 7105(b)(1)) to provide interim assistance to children who may have been subjected to a severe form of trafficking and to issue eligibility letters and conduct related activities. In issuing eligibility letters, personnel in the Administration for Children and Families will consult with the Attorney General, the Secretary of Homeland Security, and nongovernmental organizations with expertise on victims of trafficking.

Authority to train Federal staff and State and local officials to improve identification and protection for victims of a severe form of trafficking under section 107(c)(4) of the TVPA (22 U.S.C. 7105(c)(4)).

These delegations of authority supersede any prior delegations or re-delegations on these subjects to the extent such delegations or re-delegations may be inconsistent herewith.

I hereby affirm and ratify any actions taken by the Director of Refugee Resettlement and the OTIP Director, or his or her subordinates, which involved the exercise of authorities prior to the effective date of these January 27, 2016, delegations.

These authorities shall be exercised under the Department's policy on regulations and the existing delegation of authority to approve and issue regulations.

These delegations shall be exercised under financial and administrative requirements applicable to these Administration for Children and Families authorities.

The delegations listed were effective January 27, 2016.

Dated: May 12, 2016.

**Mark H. Greenberg,**

*Acting Assistant Secretary for Children and Families.*

[FR Doc. 2016-11731 Filed 5-17-16; 8:45 am]

**BILLING CODE 4184-34-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2016-N-0001]

#### Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.

**DATES:** The meeting will be held on June 28, 2016, from 8 a.m. to 5 p.m.

**ADDRESSES:** Hilton Washington DC/ Rockville Hotel & Executive Meeting Center, Plaza Ballroom, 1750 Rockville Pike, Rockville, MD 20852. The hotel's telephone number is 301-468-1100. Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: <http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm>.

**FOR FURTHER INFORMATION CONTACT:** LaToya Bonner, Center for Drug Evaluation and Research, Food and

Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, [EMDAC@fda.hhs.gov](mailto:EMDAC@fda.hhs.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at <http://www.fda.gov/AdvisoryCommittees/default.htm> and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

#### SUPPLEMENTARY INFORMATION:

**Agenda:** The committee will discuss supplemental new drug application (sNDA) 204629, empagliflozin (JARDIANCE) tablets, and sNDA 206111, empagliflozin and metformin hydrochloride (SYNJARDY) tablets. Both sNDAs are sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., for the proposed additional indication in adult patients with type 2 diabetes mellitus and high cardiovascular risk to reduce the risk of all-cause mortality by reducing the incidence of cardiovascular death and to reduce the risk of cardiovascular death or hospitalization for heart failure.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link.

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before June 14, 2016. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or

arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before June 6, 2016. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by June 7, 2016.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact LaToya Bonner at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at <http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 11, 2016.

**Jill Hartzler Warner,**

*Associate Commissioner for Special Medical Programs.*

[FR Doc. 2016-11678 Filed 5-17-16; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Agency Information Collection Activities: Proposed Collection: Public Comment Request

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement for opportunity for public comment on proposed data collection projects (Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995), the Health Resources and Services Administration (HRSA) announces